MedPath

High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
Registration Number
NCT00082797
Lead Sponsor
Eastern Cooperative Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop tumor cells from dividing so they stop growing or die. Leucovorin may decrease side effects caused by high-dose methotrexate.

PURPOSE: This phase II trial is studying how well giving high-dose methotrexate together with leucovorin works in treating patients with newly diagnosed glioblastoma multiforme.

Detailed Description

OBJECTIVES:

Primary

* Determine the response in patients with newly diagnosed glioblastoma multiforme treated with high-dose methotrexate and leucovorin calcium.

Secondary

* Determine the acute toxicity of this regimen in these patients.

* Determine the duration of survival of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive high-dose methotrexate IV over 4 hours on day 1 and oral or IV leucovorin calcium every 6 hours beginning on day 2 and continuing until blood methotrexate levels are acceptable. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients then receive standard radiotherapy with or without chemotherapy. Patients with disease progression proceed to standard radiotherapy with or without chemotherapy upon stopping methotrexate therapy.

Patients are followed at 30 days and then every 2 months for up to 2 years.

PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate (complete and partial)
Secondary Outcome Measures
NameTimeMethod
Frequency of toxicity

Trial Locations

Locations (65)

Rush-Copley Cancer Care Center

πŸ‡ΊπŸ‡Έ

Aurora, Illinois, United States

St. Joseph Medical Center

πŸ‡ΊπŸ‡Έ

Bloomington, Illinois, United States

Graham Hospital

πŸ‡ΊπŸ‡Έ

Canton, Illinois, United States

Memorial Hospital

πŸ‡ΊπŸ‡Έ

Carthage, Illinois, United States

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Hematology and Oncology Associates

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

University of Illinois Cancer Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Veterans Affairs Medical Center - Chicago Westside Hospital

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Mercy Hospital and Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Swedish Covenant Hospital

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Scroll for more (55 remaining)
Rush-Copley Cancer Care Center
πŸ‡ΊπŸ‡ΈAurora, Illinois, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.